Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity

ABSTRACT: Key Points PCSK9 protects against diet-induced renal injury in both cultured cells and mice by enhancing the degradation of renal cluster of differentiation 36 (CD36). PCSK9 mAbs (evolocumab) do not block the ability of PCSK9 to bind to surface CD36, unlike its effects on degrading hepatic LDL receptor. PCSK9 mAbs (evolocumab) protect against diet-induced renal injury by enhancing the degradation of surface CD36. Visual Abstract

Background

PCSK9 modulates the uptake of circulating lipids through a range of receptors, including the low-density lipoprotein receptor (LDLR) and CD36. In the kidney, CD36 is known to contribute to renal injury through pro-inflammatory and -fibrotic pathways. In this study, we sought to investigate the role of PCSK9 in modulating renal lipid accumulatio

SUBMITTER: Byun J 

PROVIDER: S-EPMC9416829 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature